World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
82
Citations
25376
World Ranking
1053
National Ranking
481

Eric S. Daar publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Eric S. Daar sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 322 publications — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Eric S. Daar D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Eric S. Daar sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 82 D-Index — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Eric S. Daar is affiliated with the Lundquist Institute in the United States and has a primary focus in the field of Medicine, with extensive specialization in Infectious Diseases, Virology, Epidemiology, Neurology, and Emergency Medicine. Their research portfolio comprises 287 publications in Medicine, including 171 in Infectious Diseases and notable contributions to the study of SARS-CoV-2 and HIV/AIDS.

Daar's work covers a diverse array of topics, prominently featuring:

  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 Clinical Research Studies
  • HIV Research and Treatment
  • HIV/AIDS Research and Interventions
  • HIV/AIDS Drug Development and Treatment
  • SARS-CoV-2 Detection and Testing
  • Long-Term Effects of COVID-19

Their research has been published in numerous venues, demonstrating a consistent presence in the academic community. Frequent publication venues include:

  • UNC Libraries
  • The Journal of Infectious Diseases
  • Clinical Infectious Diseases
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Open Forum Infectious Diseases

Eric S. Daar has collaborated frequently with a number of scientists in the field, including:

  • Kara W Chew
  • Judith S. Currier
  • Michael D. Hughes
  • Joseph J. Eron
  • David A. Wohl

Recent publications by Daar or involving their contributions include:

  • Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women, 2021, New England Journal of Medicine
  • Clinical targeting of HIV capsid protein with a long-acting small molecule, 2020, Nature
  • Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial, 2021, The Lancet HIV
  • Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection, 2023, Annals of Internal Medicine
  • Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV, 2024, JAMA Cardiology

Best Publications

  • The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

    Pereyra F;Jia X;McLaren Pj

  • Antiretroviral-Drug Resistance among Patients Recently Infected with HIV

    Susan J. Little;Sarah Holte;Jean Pierre Routy;Eric S. Daar

  • Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection.

    Eric S. Daar;Tarsem Moudgil;Richard D. Meyer;David D. Ho

  • Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

    Raphael J Landovitz;Deborah Donnell;Meredith E Clement;Brett Hanscom

  • High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.

    Eric S. Daar;Xi Ling Li;Tarsem Moudgil;David D. Ho

  • Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

    Grace A. McComsey;Douglas Kitch;Eric S. Daar;Camlin Tierney

  • Modeling plasma virus concentration during primary HIV infection.

    Max A. Stafford;Lawrence Corey;Yunzhen Cao;Eric S. Daar

  • A Small-molecule Inhibitor Directed against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor

    Benjamin J. Doranz;Kathie Grovit-Ferbas;Matthew P. Sharron;Si-Hua Mao

  • Reduced Antiretroviral Drug Susceptibility Among Patients With Primary HIV Infection

    Susan J. Little;Eric S. Daar;Richard T. D'Aquila;Philip H. Keiser

  • NATURALLY OCCURRING DOMINANT RESISTANCE MUTATIONS TO HEPATITIS C VIRUS PROTEASE AND POLYMERASE INHIBITORS IN TREATMENT-NAIVE PATIENTS

    Thomas Kuntzen;Joerg Timm;Andrew Berical;Niall Lennon

  • Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

    Paul E. Sax;Camlin Tierney;Ann C. Collier;Margaret A. Fischl

  • Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

    Joel Gallant;Adriano Lazzarin;Anthony Mills;Chloe Orkin

  • Diagnosis of Primary HIV-1 Infection

    Eric S. Daar;Susan Little;Jacqui Pitt;Joanne Santangelo

  • Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.

    Matthew C. Strain;Susan J. Little;Eric S. Daar;Diane V. Havlir

  • Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

    Eric S. Daar;Camlin Tierney;Margaret A. Fischl;Paul E. Sax

  • Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment.

    Jarek Harezlak;Steven Buchthal;Michael Taylor;Giovanni Schifitto

  • Changes in Plasma HIV RNA Levels and CD4+ Lymphocyte Counts Predict Both Response to Antiretroviral Therapy and Therapeutic Failure

    William A. O'Brien;Pamela M. Hartigan;Eric S. Daar;Michael S. Simberkoff

  • Clinical targeting of HIV capsid protein with a long-acting small molecule.

    John O. Link;Martin S. Rhee;Winston C. Tse;Jim Zheng

  • Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.

    Ann R Falsey;Magdalena E Sobieszczyk;Ian Hirsch;Stephanie Sproule

  • Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody.

    D. D. Ho;J. A. Mckeating;Xi Ling Li;T. Moudgil

  • Antibody from Patients with Acute Human Immunodeficiency Virus (HIV) Infection Inhibits Primary Strains of HIV Type 1 in the Presence of Natural-Killer Effector Cells

    Donald N. Forthal;Gary Landucci;Eric S. Daar

  • Reduced antiretroviral drug susceptibility among patients with primary HIV infection, JAMA 282: 1142-9

    Susan J. Little;E. S. Daar;R. T. D'Aquila;P. H. Keiser

Frequent Co-Authors

Paul E. Sax
Paul E. Sax Brigham and Women's Hospital
Douglas D. Richman
Douglas D. Richman University of California, San Diego
Susan J. Little
Susan J. Little University of California, San Diego
Richard Haubrich
Richard Haubrich University of California, San Diego
Davey M. Smith
Davey M. Smith University of California, San Diego
David W. Haas
David W. Haas Vanderbilt University Medical Center
Ann C. Collier
Ann C. Collier University of Washington
Grace A. McComsey
Grace A. McComsey Case Western Reserve University
Roy M. Gulick
Roy M. Gulick Cornell University
Ronald A. Cohen
Ronald A. Cohen University of Florida

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees related to Microbiology can open doors to diverse career opportunities, especially for those facing unique challenges. For individuals with a past conviction, pursuing online degrees for felons offers a promising way to build a new professional path in healthcare or related fields.

For those interested in blending biology and patient care, becoming a Functional Medicine Nurse Practitioner is a growing field. Understanding the functional medicine nurse salary can help gauge financial prospects while offering a fulfilling healthcare career focused on holistic treatment.

Alternatively, career pathways in healthcare administration and data management are thriving. Becoming a Certified Professional Coder is one such option. Knowing the certified professional coder salary and related roles can guide students interested in medical billing and coding.

Health Information Management is another strategic area, combining technology with healthcare. Learning about health information management jobs salary provides insight into this in-demand field that supports clinical operations and data analytics.

Best Scientists Citing Eric S. Daar

Trending Scientists

Recently Published Articles